Illumina Inc., a global leader in genomics, has released its 2024 Corporate Social Responsibility (CSR) Report, emphasizing the company’s continued efforts to make precision health more accessible, champion sustainability, and operate with transparency and integrity. The report showcases how Illumina is integrating environmental, social, and governance (ESG) principles into its mission to improve human health through the power of genomics.
“At Illumina, our goal is to unlock the genome to transform human health—but innovation alone isn’t enough if it can’t be accessed,” said Jacob Thaysen, CEO of Illumina. “Our CSR strategy is key to ensuring that the benefits of genomics are shared broadly. We are committed to empowering people and communities, advancing health equity, and protecting the planet.”
Expanding Access to Genomics:
In 2024, Illumina's policy advocacy efforts led to expanded healthcare coverage for genomic testing, reaching an additional 100 million people globally. This brings the total number of lives with access to genomic testing to 1.4 billion—marking a significant step toward closing health equity gaps. The launch of the MiSeq™ i100 Series, a benchtop sequencer designed for simplified workflows and quicker analysis, further supports integration of genomics into routine care.
Supporting STEM Education:
To nurture the next generation of genomic leaders, Illumina has reached over 2.1 million STEM learners since 2019 through direct educational programs, nonprofit collaborations, and employee engagement efforts.
Sustainability remains central to Illumina’s operations. In 2024, the company surpassed its 2030 goal for packaging reduction, achieving an 80% decrease since 2019. The MiSeq i100 Series also contributed to a 35% reduction in climate impact through room-temperature reagent storage and compact packaging.
Illumina maintained its commitment to renewable energy, with 100% of global electricity sourced from renewables for the third consecutive year. Additionally, the company achieved a 45% reduction in Scope 1 and 2 greenhouse gas emissions from its 2019 baseline. Five labs also earned My Green Lab certification, the global benchmark for sustainable lab practices.
All of Illumina’s core facilities participated in third-party audit programs. The company upheld strong governance practices, with an independent Board of Directors (excluding the CEO) and an independent Board Chair. Illumina was again recognized on the Dow Jones Sustainability World and North America Indices and earned a top industry rating from ISS for corporate governance.
The full 2024 CSR Report is available on Illumina’s official CSR website.